Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.52 |
| ▸ | IRAK4 | Q9NWZ3 | 16/20 | 0.47 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768771 | 0.85 | IRAK4 (0.50) | IRAK4 | |
| SCHEMBL2609332 | 0.84 | KMT2A (0.60) | MEN1RAB9AKMT2AASIC3TRPV3 | |
| SCHEMBL14108546 | 0.81 | KMT2A (0.56) | MEN1RAB9AKMT2AASIC3TRPV3 | |
| SCHEMBL27651071 | 0.81 | KMT2A (0.56) | MEN1RAB9AKMT2AASIC3TRPV3 | |
| SCHEMBL12137374 | 0.81 | MEN1 (0.56) | MEN1RAB9AKMT2AASIC3IRAK4 | |
| SCHEMBL14614579 | 0.80 | MEN1 (0.50) | MEN1RAB9AKMT2AASIC3IRAK4 | |
| SCHEMBL16768768 | 0.80 | RAB9A (0.50) | MEN1RAB9AKMT2AASIC3IRAK4 | |
| SCHEMBL522063 | 0.79 | CYP1A2 (0.38) | IRAK4 | |
| SCHEMBL12137380 | 0.78 | MEN1 (0.52) | MEN1RAB9AKMT2AASIC3TRPV3 | |
| SCHEMBL14089452 | 0.78 | MEN1 (0.52) | MEN1RAB9AKMT2AASIC3TRPV3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3360880-B1 | PROCESS FOR THE PREPARATION OF CIS-RUTHENIUM OR -OSMIUM COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2022-04-13 | — | — | EP | disclosed |
| EP-3303353-B1 | PROCESS | JOHNSON MATTHEY PLC (GB) | 2022-01-12 | — | — | EP | disclosed |
| US-10676494-B2 | Processes for preparing phosphine diamine complexes of ruthenium and osmium | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2020-06-09 | — | — | US | disclosed |
| EP-3656780-A2 | PROCESS FOR THE PREPARATION OF CIS-RUTHENIUM OR -OSMIUM COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2020-05-27 | — | — | EP | disclosed |
| EP-3074409-B1 | PROCESSES FOR THE PREPARATION OF RUTHENIUM OR OSMIUM COMPLEXES COMPRISING P AND N DONOR LIGANDS | JOHNSON MATTHEY PLC (GB) | 2020-04-15 | — | — | EP | disclosed |
| US-10428098-B2 | Processes for preparing and using ruthenium and osmium complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-10-01 | — | — | US | disclosed |
| US-20190233452-A1 | Process | JOHNSON MATTHEY PLC (GB) | 2019-08-01 | — | — | US | disclosed |
| US-10301337-B2 | Process | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-05-28 | — | — | US | disclosed |
| WO-2019043414-A1 | PROCESS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-20180170954-A1 | Process | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180170954-A1 | Process | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-06-21 | — | — | US | disclosed |
| US-20180148465-A1 | PROCESS | UNIVERSITA DEGLI STUDI DI UDINE (IT) | 2018-05-31 | — | — | US | disclosed |
| US-20180148465-A1 | PROCESS | UNIVERSITA DEGLI STUDI DI UDINE (IT) | 2018-05-31 | — | — | US | disclosed |
| US-9932362-B2 | Processes for the preparation of ruthenium or osmium complexes comprising P and N donor ligands | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-04-03 | — | — | US | disclosed |
| US-9932362-B2 | Processes for the preparation of ruthenium or osmium complexes comprising P and N donor ligands | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-04-03 | — | — | US | disclosed |
| US-20170081350-A1 | PROCESSES FOR THE PREPARATION OF RUTHENIUM OR OSMIUM COMPLEXES COMPRISING P AND N DONOR LIGANDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-03-23 | — | — | US | disclosed |
| US-20170081350-A1 | PROCESSES FOR THE PREPARATION OF RUTHENIUM OR OSMIUM COMPLEXES COMPRISING P AND N DONOR LIGANDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-03-23 | — | — | US | disclosed |
| WO-2016193762-A1 | PROCESS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2016-12-08 | — | — | WO | disclosed |
| WO-2015079207-A2 | PROCESS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301337-B2 | Process | OSTC, EXOSC9, OGA | MEN1 3658/4885RAB9A 3417/4885KMT2A 4826/4885 |
| US-20170081350-A1 | PROCESSES FOR THE PREPARATION OF RUTHENIUM OR OSMIUM COMPLEXES COMPRISING P AND N DONOR LIGANDS | OSTC, POP1, OGA | MEN1 3064/4885RAB9A 2614/4885KMT2A 4857/4885 |
| US-10676494-B2 | Processes for preparing phosphine diamine complexes of ruthenium and osmium | OSTC, ODC1, ITPA | MEN1 1077/4885RAB9A 1721/4885KMT2A 4361/4885 |
| US-10428098-B2 | Processes for preparing and using ruthenium and osmium complexes | OSTC, OTC, ORC3 | MEN1 2978/4885RAB9A 3023/4885KMT2A 4735/4885 |
| US-20180148465-A1 | PROCESS | OSTC, AP2S1, LGALS4 | MEN1 3951/4885RAB9A 3894/4885KMT2A 4733/4885 |
| US-20190233452-A1 | Process | OSTC, EXOSC9, OGA | MEN1 3658/4885RAB9A 3417/4885KMT2A 4826/4885 |
| US-20180170954-A1 | Process | OSTC, EXOSC9, OGA | MEN1 3658/4885RAB9A 3417/4885KMT2A 4826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.